Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Add filters

Document Type
Year range
Nucleic Acids Res ; 49(7): e37, 2021 04 19.
Article in English | MEDLINE | ID: covidwho-1066376


Multiple driver genes in individual patient samples may cause resistance to individual drugs in precision medicine. However, current computational methods have not studied how to fill the gap between personalized driver gene identification and combinatorial drug discovery for individual patients. Here, we developed a novel structural network controllability-based personalized driver genes and combinatorial drug identification algorithm (CPGD), aiming to identify combinatorial drugs for an individual patient by targeting personalized driver genes from network controllability perspective. On two benchmark disease datasets (i.e. breast cancer and lung cancer datasets), performance of CPGD is superior to that of other state-of-the-art driver gene-focus methods in terms of discovery rate among prior-known clinical efficacious combinatorial drugs. Especially on breast cancer dataset, CPGD evaluated synergistic effect of pairwise drug combinations by measuring synergistic effect of their corresponding personalized driver gene modules, which are affected by a given targeting personalized driver gene set of drugs. The results showed that CPGD performs better than existing synergistic combinatorial strategies in identifying clinical efficacious paired combinatorial drugs. Furthermore, CPGD enhanced cancer subtyping by computationally providing personalized side effect signatures for individual patients. In addition, CPGD identified 90 drug combinations candidates from SARS-COV2 dataset as potential drug repurposing candidates for recently spreading COVID-19.

Algorithms , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Drug Therapy, Combination , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Precision Medicine/methods , Breast Neoplasms/classification , COVID-19/drug therapy , COVID-19/genetics , Datasets as Topic , Drug Repositioning , Drug Synergism , Drug-Related Side Effects and Adverse Reactions , Gene Expression Regulation, Neoplastic/genetics , Genes, Neoplasm/genetics , Humans , Risk Assessment , Workflow